caspofungin acetate
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Invasive Candidiasis
Conditions
Invasive Candidiasis
Trial Timeline
Jan 1, 2006 → Mar 1, 2008
NCT ID
NCT00250432About caspofungin acetate
caspofungin acetate is a phase 3 stage product being developed by Merck for Invasive Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00250432. Target conditions include Invasive Candidiasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00635648 | Phase 3 | Completed |
| NCT00330395 | Phase 2 | Completed |
| NCT00250432 | Phase 3 | Completed |
| NCT00379964 | Phase 3 | Completed |
| NCT00292071 | Phase 2 | Completed |
| NCT00082524 | Phase 2 | Completed |
Competing Products
20 competing products in Invasive Candidiasis